JUNE 2012
VOLUME 5 I NUMBER 3 I SPECIAL FEATURE
THE PEER-REVIEWED FORUM FOR EVIDENCE IN BENEFIT DESIGN ™
FOR PAYERS, PURCHASERS, POLICYMAKERS, AND OTHER HEALTHCARE STAKEHOLDERS
PAYERS’ GUIDE TO NEW FDA APPROVALS ™
INTRODUCTION: New Drug Approvals in 2011 FDA Approvals of Brand-Name Prescription Drugs in 2011 Ruxolitinib a New Oral Option for Patients with Intermediate- or High-Risk Myelofibrosis Disorders An Overview of Metastatic Castration-Resistant Prostate Cancer and Treatment Tradjenta® (linagliptin) Tablets The 2012 Drug Pipeline
Special Feature
©2012 Engage Healthcare Communications, LLC www.AHDBonline.com